| Identification | Back Directory | [Name]
troponin I type 3 (cardiac) | [CAS]
339163-65-4 | [Synonyms]
CMH7
RCM1
cTnI
CMD2A
CMD1FF
RCM 1 NEW
Troponin I ELISA Kit
troponin I type 3 (cardiac)
Anti-TNNI3 antibody produced in goat
Monoclonal Anti-TNNI3 antibody produced in mouse
3-Pyridinecarbonitrile, 2-[[2-oxo-2-(2-thienyl)ethyl]thio]-4,6-di-2-thienyl- | [Molecular Formula]
C20H12N2OS4 | [MDL Number]
MFCD00742440 | [MOL File]
339163-65-4.mol | [Molecular Weight]
424.58 |
| Chemical Properties | Back Directory | [Boiling point ]
632.8±55.0 °C(Predicted) | [density ]
1.49±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,Room temperature | [solubility ]
DMSO : 16.67 mg/mL (39.26 mM) | [form ]
buffered aqueous solution | [pka]
-1.42±0.37(Predicted) | [color ]
Off-white to gray | [biological source]
mouse | [InChIKey]
DCCYTKKDAZEVLY-UHFFFAOYSA-N | [SMILES]
[s]1c(ccc1)c2nc(c(c(c2)c4[s]ccc4)C#N)SCC(=O)c3[s]ccc3 |
| Hazard Information | Back Directory | [Uses]
RCM-1 is a forkhead box M1 (FOXM1) inhibitor with an EC50 of 0.72 μM in U2OS cells. RCM-1 blocks the nuclear localization and increased the proteasomal degradation of FOXM1. RCM-1 can be used for asthma and other chronic airway diseases research[1]. | [General Description]
Troponin I3, cardiac type (TNNI3), also known as cardiac troponin I (cTnI), is the inhibitory element of troponin. It possesses an inhibitory peptide (IP) domain and a switch peptide (SP) domain that is located N-terminal of the IP domain. The gene encoding TNNI3 is localized on human chromosome 19q13.42. | [Biochem/physiol Actions]
Troponin I3, cardiac type (TNNI3) or cardiac troponin I (cTnI) modulates the diastolic function of the heart. Low expression of TNNI3 is associated with cardiac diastolic dysfunction. Elevated expression of the protein indicates cardiac injury. TNNI3 is a biomarker for myocardial infarction and mutations in the gene encoding it have been linked to hypertrophic cardiomyopathy. | [in vivo]
RCM-1 reduces airway resistance, increased lung compliance, and decreased proinflammatory cytokine production in mice exposed to the house dust mite and interleukin-13 (IL-13), which triggers goblet cell metaplasia. In mice, RCM-1 reduces IL-13 and STAT6 signaling and prevented the expression of the STAT6 target genes Spdef and Foxa3[1]. | [storage]
Store at -20°C | [References]
[1] Lifeng Sun, et al. The FOXM1 inhibitor RCM-1 suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. Sci Signal. 2017 Apr 18;10(475):eaai8583. DOI:10.1126/scisignal.aai8583 |
|
|